Sustained release intraocular implants and methods for treating ocular vasculopathies
First Claim
Patent Images
1. A biodegradable intraocular implant comprising:
- an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant for a time effective to reduce ocular vascular occlusion in an eye in which the implant is placed, the time being at least about one week after the implant is placed in the eye.
3 Assignments
0 Petitions
Accused Products
Abstract
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
184 Citations
42 Claims
-
1. A biodegradable intraocular implant comprising:
an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant for a time effective to reduce ocular vascular occlusion in an eye in which the implant is placed, the time being at least about one week after the implant is placed in the eye. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 28, 29, 30, 31, 32, 33)
-
21. A method of making a biodegradable intraocular implant, comprising the step of:
- extruding a mixture of an alpha-2 adrenergic receptor agonist and a biodegradable polymer component to form a biodegradable material that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant for a time effective to reduce ocular vascular occlusion in an eye in which the implant is placed, the time being at least about one week after the implant is placed in the eye.
- View Dependent Claims (22, 23, 24, 25, 26, 27)
- 34. A method of treating glaucoma, the method comprising the step of placing a biodegradable intraocular implant comprising an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer in an eye, thereby treating glaucoma.
- 38. A method for improving or maintaining vision in a patient in need thereof, comprising the step of placing a biodegradable intraocular implant comprising an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer in an eye, thereby improving or maintaining vision of the patient.
-
41. A biodegradable intraocular implant comprising:
an alpha-2 adrenergic receptor agonist and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of the alpha-2 adrenergic receptor agonist from the implant for at least about one week after the implant is placed in the eye.
-
42. The implant of claim 42, wherein the alpha-2 adrenergic receptor agonist is brimonidine, salts thereof, and mixtures thereof.
Specification